Table 5.
Time of first and last use of HBV antiviral prophylaxis relative to rituximab treatment
| Baseline of HBV infection status | Antiviral prophylaxis | First use of antiviral prophylaxis | Last use of antiviral prophylaxis | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Earlier than first use of rituximab | Later than first use of rituximab | Earlier than last use of rituximab | Later than last use of rituximab | ||||||
| Number of cases | Median days | Number of cases | Median days | Number of cases | Median days | Number of cases | Median days | ||
| HBsAg+ (n = 24) | Adefovir dipivoxil | 2 | 3.5 (6, 1) | 0 | NA | 0 | NA | 3 | 1113 (473, 1251) |
| Entecavir | 3 | 1 (1, 1) | 1 | 1 (1, 1) | 0 | NA | 4 | 137.5 (6, 1187) | |
| Lamivudine | 3 | 1 (1, 1) | 2 | 14.5 (2, 27) | 0 | NA | 9 | 1111 (213, 1294) | |
| HBsAg−/HBcAb+ (n = 69) | Entecavir | 0 | NA | 1 | 21 (21, 21) | 0 | NA | 1 | 1096 (1096, 1096) |
| Lamivudine | 2 | 1 (1, 1) | 2 | 69.5 (20, 119) | 0 | NA | 8 | 884 (2, 1531) | |
Median data are reported as median (range). HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; HBcAb: Hepatitis B core antibody; NA: Not applicable.